Improving Therapeutic Adherence and Reducing Therapeutic Inertia in the Management of People with Cardiometabolic Diseases: A Call-to-Action from the Middle East.

IF 3.4 3区医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL

Advances in Therapy Pub Date : 2025-01-22 DOI:10.1007/s12325-024-03103-5

Wael Almahmeed, Zainab Alabadla, Fatheya Al Awadi, Dalal Alrohmaihi, Mostafa AlShamiri, Hussein Elbadawi, Hassan El-Tamimi, Abdel-Nasser Elzouki, Mohamed Farghaly, Khadija Hafidh, Mohamed Hassanein, Adel Khalifa Hamad, Kamlesh Khunti, Hani Sabbour, Aletta E Schutte

{"title":"Improving Therapeutic Adherence and Reducing Therapeutic Inertia in the Management of People with Cardiometabolic Diseases: A Call-to-Action from the Middle East.","authors":"Wael Almahmeed, Zainab Alabadla, Fatheya Al Awadi, Dalal Alrohmaihi, Mostafa AlShamiri, Hussein Elbadawi, Hassan El-Tamimi, Abdel-Nasser Elzouki, Mohamed Farghaly, Khadija Hafidh, Mohamed Hassanein, Adel Khalifa Hamad, Kamlesh Khunti, Hani Sabbour, Aletta E Schutte","doi":"10.1007/s12325-024-03103-5","DOIUrl":null,"url":null,"abstract":"<p><p>Hypertension, dyslipidemia, and type 2 diabetes are highly prevalent and poorly controlled cardiometabolic diseases in the Middle East. Therapeutic non-adherence and therapeutic inertia are major contributors to this suboptimal disease control. Regardless of the cardiometabolic disease, evidence-based solutions may be used to improve therapeutic non-adherence and overcome inertia, and thereby help to alleviate the heavy burden of cardiovascular disease in the Middle East. Such solutions include the routine and early use of single-pill combinations, educational initiatives for patients, and multidisciplinary team-based care. This article highlights these and other potential solutions for therapeutic non-adherence and inertia, as discussed at the 2024 Evidence in the Cardiometabolic Environment (EVIDENT) Summit. There is now a 'call-to-action' from healthcare providers and other stakeholder groups to ensure that the solutions discussed at this meeting are implemented within health systems in the Middle East to significantly improve cardiovascular outcomes.Infographic available for this article.</p>","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":" ","pages":""},"PeriodicalIF":3.4000,"publicationDate":"2025-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12325-024-03103-5","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Hypertension, dyslipidemia, and type 2 diabetes are highly prevalent and poorly controlled cardiometabolic diseases in the Middle East. Therapeutic non-adherence and therapeutic inertia are major contributors to this suboptimal disease control. Regardless of the cardiometabolic disease, evidence-based solutions may be used to improve therapeutic non-adherence and overcome inertia, and thereby help to alleviate the heavy burden of cardiovascular disease in the Middle East. Such solutions include the routine and early use of single-pill combinations, educational initiatives for patients, and multidisciplinary team-based care. This article highlights these and other potential solutions for therapeutic non-adherence and inertia, as discussed at the 2024 Evidence in the Cardiometabolic Environment (EVIDENT) Summit. There is now a 'call-to-action' from healthcare providers and other stakeholder groups to ensure that the solutions discussed at this meeting are implemented within health systems in the Middle East to significantly improve cardiovascular outcomes.Infographic available for this article.

查看原文本刊更多论文

提高心脏代谢疾病患者治疗依从性和减少治疗惰性：来自中东的行动呼吁。

高血压、血脂异常和2型糖尿病是中东地区非常普遍且控制不佳的心脏代谢疾病。治疗不依从性和治疗惰性是导致这种次优疾病控制的主要原因。无论心血管代谢疾病是什么，循证解决方案都可用于改善治疗不依从性和克服惰性，从而有助于减轻中东地区心血管疾病的沉重负担。这些解决方案包括常规和早期使用单药组合，对患者的教育倡议以及多学科团队护理。这篇文章强调了这些和其他治疗不依从和惯性的潜在解决方案，正如2024年心脏代谢环境证据（Evidence in the cardimetabolic Environment，简称Evidence）峰会上讨论的那样。现在，卫生保健提供者和其他利益攸关方团体发出了“行动呼吁”，以确保在中东的卫生系统内实施本次会议讨论的解决方案，以显著改善心血管疾病的预后。本文提供的信息图。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Advances in Therapy 医学-药学

CiteScore

7.20

自引率

2.60%

发文量

353

审稿时长

6-12 weeks

期刊介绍： Advances in Therapy is an international, peer reviewed, rapid-publication (peer review in 2 weeks, published 3–4 weeks from acceptance) journal dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of therapeutics and interventions (including devices) across all therapeutic areas. Studies relating to diagnostics and diagnosis, pharmacoeconomics, public health, epidemiology, quality of life, and patient care, management, and education are also encouraged. The journal is of interest to a broad audience of healthcare professionals and publishes original research, reviews, communications and letters. The journal is read by a global audience and receives submissions from all over the world. Advances in Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of all scientifically and ethically sound research.